ClinicalTrials.gg
Enrolling by invitationNCT06388252Updated Feb 19, 2026

Electrochemotherapy Changes in Tumor Microenvironment of Cutaneous and Subcutaneous Metastases in Melanoma Patients

An interventional study of Electrochemotherapy with Intratumoral Cysplatin and Electrochemotherapy with Intravenous Bleomycin in Cutaneous Malignant Melanoma, sponsored by Institute of Oncology Ljubljana. Enrolling by invitation at 1 site in Slovenia. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Institute of Oncology Ljubljana · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Nov 2023, registered Apr 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
18 Years to 100 Years
Sex
All
01

Study summary

In the last 10 years, the treatment of metastatic cutaneous melanoma has changed dramatically. The new systemic treatment with immunotherapy has led to a dramatic improvement in quality of life and overall survival. Systemic treatment means that the patient receives the drug as an infusion into a vein. Unfortunately, investigators know that immunotherapy is not equally successful in all patients. Recent studies have shown that the success of the treatment is not only influenced by the cellular composition of the metastasis, but also by its surroundings. This is called tumor microenvironment. Depending on the differences in the composition of this microenvironment, some metastases can be described as immunologically hot and others as immunologically cold. Immunologically hot metastases respond better to immunotherapy than immunologically cold metastases.

Studies have shown that with some interventions can change the tumor microenvironment from being immune-cold to being immune-hot. Electrochemotherapy is one of the interventions that might improve the efficacy of immunotherapy in cutaneous melanoma. Electrochemotherapy is an established method for the local treatment of tumors, in which only a certain tumor is treated with special electrodes, to which a weak electric current is applied. Investigators hypothesize that electrochemotherapy stimulates the body's own immune response and enables more effective treatment. Since immunotherapy also stimulates the body's own immune response to cutaneous melanoma cells, the interaction of the two drugs could be even more successful. Recent research results support this assumption.

The primary objective is to evaluate the changes in the tumor microenvironment of cutaneous and subcutaneous melanoma metastases induced by electrochemotherapy, based on the histologic analysis of treated and untreated metastases before and after treatment. The secondary aim is to determine whether the changes in the tumor microenvironment differ depending on the chemotherapeutic agent used.

The results will help Investigators better understand the synergistic effects of electrochemotherapy and immunotherapy on cutaneous melanoma metastases. The combination of systemic immunotherapy and electrochemotherapy could become an important treatment method for patients with metastatic melanoma.

Read the detailed description

The study is prospective. The primary objective is to evaluate the changes in the tumor microenvironment of cutaneous and subcutaneous melanoma metastases induced by electrochemotherapy (ECT), based on the histologic analysis of treated and untreated metastases before and after treatment. The secondary aim is to determine whether the changes in the tumor microenvironment differ depending on the chemotherapeutic agent used.

In the study 10-15 patients will be enrolled and devided in two arms, ECT with bleomycin and ECT with cysplatin.

ECT will be offered to patients with cuteaneous melanoma and at least 5 in-transit or distant cutaneous and/or subcutaneous melanoma metastases regardless of previous treatments. The decision will be made in a multidisciplinary tumor board. The choice of chemotherapeuthic drug will depend on the size and number of lesions to be treated. Inclusion in the study has no influence on the decision regarding the timing of treatment with immunotherapy. Treatment with immunotherapy will later be included as a factor in the statistical analysis.

ECT will be performed according to the standard operating procedures for the treatment of cutaneous and subcutaneous tumors with ECT. ECT will be performed within 8 - 28 minutes after intravenous bolus administration of bleomycin (15.000 IU/m2 BSA) or directly after the intratumorally administration of cysplatin (0,5-2 mg/cm3 tumor). CliniporatorTM (IGEA S.P.A., Carpi, Italy) will be used to apply the pulses (8 pulses, 1300 V/cm, 100 μs, 5 kHz). Triggering of the electrical pulses will be synchronized with ECG signals, through the ECG triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart. The type of electrode used will be selected according to the size and location of the tumors.

One cutaneous/subcutaneous metastasis will be excised before ECT. One treated cutaneous/subcutaneous metastasis will be excised 2-4 and 9-13 days after the procedure. An untreated cutaneous/subcutaneous metastasis will be excised on day 9-13. The excisions will be performed under local anesthesia. All patients will be enrolled in the study after the procedures and the study have been explained to them in detail and they have signed an informed consent form. A venous blood sample will be taken at the same time points (before ECT, 2-4 days and 9-13 days after ECT).

Histological examination, assessment of the degree of regression and the presence of tumor infiltrating lymphocytes (TIL) will be performed according to standardized procedures on 2-3 μm thick tissue sections, previously fixed in formalin and embedded in paraffin (FFPE), stained with the hematoxylin-eosin (HE) staining method.

Immunohistochemical characterization of the tumor microenvironment will be performed on 2-4 μm thick tissue sections pre-fixed in formalin and embedded in paraffin. Investigators will use commercially available primary monoclonal antibodies to define the tumor inflammatory infiltrate, stroma and vasculature. We will use the following antibodies: CD3, CD4, CD8, CD56, CD163, FoxP3, ERG, PGM1, CD274 (PD-L1). The choice of antibodies used and the method of pathohistologic analysis may change depending on the results. Specific binding of primary antibodies will be visualized using the recommended three-step detection system OptiView DAB IHC Detection Kit (Cat. No. 760-700; manufactured by Ventana ROCHE inc., Tucson, AZ, USA) according to the manufacturer's instructions. The analysis will be performed by two independent pathologists.

Investigators will also collect the information about previous treatments for cutaneous melanoma and photographic documentation of the effectiveness of ECT treatment. Patients will also fill out internationally recognized, validated quality of life questionnaires (EORTC QLQ-C 30 and EQ-5D-5L) at entollment, after ECT, 3 months, 6 months and 12 months after ECT and then once a year during the follow-up period.

02

Conditions studied

  • Cutaneous Malignant Melanoma

Keywords

  • In-transit melanoma metastases
  • Cutaneous and subcutaneous melanoma metastases
  • Electrochemotherapy
  • Bleomycin
  • Cysplatin
03

In context

Melanoma, Cutaneous Malignant

17 studies on the registry are indexed under Melanoma, Cutaneous Malignant; 5 are open to participants now.

This study's planned enrollment of 10 is below the median of 33 across 11 interventional studies indexed under Melanoma, Cutaneous Malignant.

Browse Melanoma, Cutaneous Malignant studies →

Lead sponsor

Institute of Oncology Ljubljana is the lead sponsor of 81 studies on the registry; 26 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • more than 4 and/or histologically confirmed intransit or distant cutaneous/subcutaneous cutaneous melanoma
  • ECT should be proposed as a treatment in the multidisciplinary tumor board
  • cutaneous/subcutaneous melanoma metastases, that can be excised under local anesthesia with primary wound closure, minimal morbidity of the procedure (risk of complications \< 5%) and nocosmetic or functional consequences of the procedure
  • stage IIIB, IIIC or IV of the disease
  • age over 18 years
  • performance status World Health Organization more than 2
  • patients must give

Exclusion criteria

Exclusion Criteria:

  • age less than 18 years
  • polimorbidity
  • performance status World Health Organization more than 2
  • high risk for intervention under general anesthesia;
  • wound closure would require coverage with a skin graft or local flap;
  • undesirable cosmetic or functional consequences would be expected (face, extensor side of joints)
  • patients incapable of understanding the aim of the study or disagree with the entering into the clinical study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Active comparator
    Electrochemotherapy with Intratumoral Cysplatin

    ECT will be performed directly after the intratumorally administration of cysplatin (0,5-2 mg/cm3 tumor). CliniporatorTM (IGEA S.P.A., Carpi, Italy) will be used to apply the pulses (8 pulses, 1300 V/cm, 100 μs, 5 kHz). Triggering of the electrical pulses will be synchronized with ECG signals, through the ECG triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart. The type of electrode used will be selected according to the size and location of the tumors.

    Procedure: Electrochemotherapy with Intratumoral Cysplatin

  • Active comparator
    Electrochemotherapy with Intravenous Bleomycin

    ECT will be performed within 8 - 28 minutes after intravenous bolus administration of bleomycin (15.000 IU/m2 BSA). CliniporatorTM (IGEA S.P.A., Carpi, Italy) will be used to apply the pulses (8 pulses, 1300 V/cm, 100 μs, 5 kHz). Triggering of the electrical pulses will be synchronized with ECG signals, through the ECG triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart. The type of electrode used will be selected according to the size and location of the tumors.

    Procedure: Electrochemotherapy with Intravenous Bleomycin

Interventions

  • ProcedureElectrochemotherapy with Intratumoral Cysplatin

    ECT will be performed directly after the intratumorally administration of cysplatin (0,5-2 mg/cm3 tumor). CliniporatorTM (IGEA S.P.A., Carpi, Italy) will be used to apply the pulses (8 pulses, 1300 V/cm, 100 μs, 5 kHz). Triggering of the electrical pulses will be synchronized with ECG signals, through the ECG triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart. The type of electrode used will be selected according to the size and location of the tumors.

  • ProcedureElectrochemotherapy with Intravenous Bleomycin

    ECT will be performed within 8 - 28 minutes after intravenous bolus administration of bleomycin (15.000 IU/m2 BSA). CliniporatorTM (IGEA S.P.A., Carpi, Italy) will be used to apply the pulses (8 pulses, 1300 V/cm, 100 μs, 5 kHz). Triggering of the electrical pulses will be synchronized with ECG signals, through the ECG triggering device AccuSync to avoid delivery of pulses in vulnerable period of the heart. The type of electrode used will be selected according to the size and location of the tumors.

06

What researchers measure

Primary outcomes

  1. Change in Tumor-Infiltrating Lymphocytes (TIL) Score Assessed by MIA Scoring System (Azimi et al.)

    Tumor-infiltrating lymphocytes (TILs) will be evaluated semi-quantitatively using the MIA scoring system (Azimi et al.) in tissue samples from treated and untreated cutaneous/subcutaneous melanoma metastases. Assessment will be performed independently by two experienced pathologists.

    Time frame: Before electrochemotherapy (baseline), 2-4 days after electrochemotherapy, and 9-13 days after electrochemotherapy

  2. Lymphocyte and Macrophage Distribution Density in Tumor Microenvironment Assessed by Park CH Method

    Distribution densities of lymphocytes and macrophages in the tumor microenvironment will be estimated according to Park CH et al. in biopsies of treated and untreated melanoma metastases. Assessment will be performed independently by two experienced pathologists.

    Time frame: Before electrochemotherapy (baseline), 2-4 days after electrochemotherapy, and 9-13 days after electrochemotherapy

  3. Number of Immune Marker-Positive Cells per mm² in Tumor Tissue Assessed by Immunohistochemistry (IHC)

    The number of CD3+, CD4+, CD8+, CD56+, CD163+, FoxP3+, PGM1+, and PD-L1 (CD274)+ cells per mm² will be quantified by immunohistochemistry (IHC) in tissue samples from treated and untreated melanoma metastases. Results will be evaluated independently by two experienced pathologists.

    Time frame: Before electrochemotherapy (baseline), 2-4 days after electrochemotherapy, and 9-13 days after electrochemotherapy

Secondary outcomes

  1. Difference in Change of Tumor-Infiltrating Lymphocytes (TIL) Score (MIA Scoring) Between Bleomycin and Cisplatin Electrochemotherapy

    Changes in semi-quantitative tumor-infiltrating lymphocyte (TIL) score assessed using the MIA scoring system (Azimi et al.) will be compared between patients treated with electrochemotherapy using intravenous bleomycin versus intratumoral cisplatin.

    Time frame: Before electrochemotherapy (baseline), 2-4 days after electrochemotherapy, and 9-13 days after electrochemotherapy

  2. Difference in Immune Cell Density and Immune Marker-Positive Cells per mm² Between Bleomycin and Cisplatin Electrochemotherapy

    Changes in lymphocyte/macrophage distribution density (Park CH method) and the number of immune marker-positive cells per mm² assessed by immunohistochemistry (CD3, CD4, CD8, CD56, CD163, FoxP3, ERG, PGM1, PD-L1/CD274) will be compared between patients treated with electrochemotherapy using intravenous bleomycin versus intratumoral cisplatin.

    Time frame: Before electrochemotherapy (baseline), 2-4 days after electrochemotherapy, and 9-13 days after electrochemotherapy

07

Study locations

1 site
08

References and documents

Publications

  • Zadnik V, Primic Zakelj M, Lokar K, Jarm K, Ivanus U, Zagar T. Cancer burden in slovenia with the time trends analysis. Radiol Oncol. 2017 Feb 22;51(1):47-55. doi: 10.1515/raon-2017-0008. eCollection 2017 Mar 1. PubMed 28265232 ↗
  • Littman DR. Releasing the Brakes on Cancer Immunotherapy. Cell. 2015 Sep 10;162(6):1186-90. doi: 10.1016/j.cell.2015.08.038. PubMed 26359975 ↗
  • Goggins CA, Khachemoune A. The use of electrochemotherapy in combination with immunotherapy in the treatment of metastatic melanoma: a focused review. Int J Dermatol. 2019 Aug;58(8):865-870. doi: 10.1111/ijd.14314. Epub 2018 Nov 26. PubMed 30479009 ↗
  • Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Del Marmol V, Dreno B, Fargnoli MC, Forsea AM, Grob JJ, Hoeller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbe C, Lytvynenko B, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stratigos AJ, Van Akkooi ACJ, Vieira R, Zalaudek I, Lorigan P; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization for Research and Treatment of Cancer (EORTC). European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022. Eur J Cancer. 2022 Jul;170:256-284. doi: 10.1016/j.ejca.2022.04.018. Epub 2022 May 24. PubMed 35623961 ↗
  • Quaglino P, Mortera C, Osella-Abate S, Barberis M, Illengo M, Rissone M, Savoia P, Bernengo MG. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol. 2008 Aug;15(8):2215-22. doi: 10.1245/s10434-008-9976-0. Epub 2008 May 23. PubMed 18498012 ↗
  • Kunte C, Letule V, Gehl J, Dahlstroem K, Curatolo P, Rotunno R, Muir T, Occhini A, Bertino G, Powell B, Saxinger W, Lechner G, Liew SH, Pritchard-Jones R, Rutkowski P, Zdzienicki M, Mowatt D, Sykes AJ, Orlando A, Mitsala G, Rossi CR, Campana L, Brizio M, de Terlizzi F, Quaglino P, Odili J; InspECT (the International Network for Sharing Practices on Electrochemotherapy). Electrochemotherapy in the treatment of metastatic malignant melanoma: a prospective cohort study by InspECT. Br J Dermatol. 2017 Jun;176(6):1475-1485. doi: 10.1111/bjd.15340. Epub 2017 Apr 26. PubMed 28118487 ↗
  • Campana LG, Valpione S, Mocellin S, Sundararajan R, Granziera E, Sartore L, Chiarion-Sileni V, Rossi CR. Electrochemotherapy for disseminated superficial metastases from malignant melanoma. Br J Surg. 2012 Jun;99(6):821-30. doi: 10.1002/bjs.8749. Epub 2012 Apr 17. PubMed 22508342 ↗
  • Cadossi R, Ronchetti M, Cadossi M. Locally enhanced chemotherapy by electroporation: clinical experiences and perspective of use of electrochemotherapy. Future Oncol. 2014 Apr;10(5):877-90. doi: 10.2217/fon.13.235. PubMed 24799067 ↗
  • Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol. 2013 Jan;39(1):4-16. doi: 10.1016/j.ejso.2012.08.016. Epub 2012 Sep 11. PubMed 22980492 ↗
  • Gehl J, Sersa G, Matthiessen LW, Muir T, Soden D, Occhini A, Quaglino P, Curatolo P, Campana LG, Kunte C, Clover AJP, Bertino G, Farricha V, Odili J, Dahlstrom K, Benazzo M, Mir LM. Updated standard operating procedures for electrochemotherapy of cutaneous tumours and skin metastases. Acta Oncol. 2018 Jul;57(7):874-882. doi: 10.1080/0284186X.2018.1454602. Epub 2018 Mar 25. PubMed 29577784 ↗
  • Sersa G, Teissie J, Cemazar M, Signori E, Kamensek U, Marshall G, Miklavcic D. Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer. Cancer Immunol Immunother. 2015 Oct;64(10):1315-27. doi: 10.1007/s00262-015-1724-2. Epub 2015 Jun 12. PubMed 26067277 ↗
  • Polajzer T, Jarm T, Miklavcic D. Analysis of damage-associated molecular pattern molecules due to electroporation of cells in vitro. Radiol Oncol. 2020 Jul 29;54(3):317-328. doi: 10.2478/raon-2020-0047. PubMed 32726295 ↗
  • Sersa G, Ursic K, Cemazar M, Heller R, Bosnjak M, Campana LG. Biological factors of the tumour response to electrochemotherapy: Review of the evidence and a research roadmap. Eur J Surg Oncol. 2021 Aug;47(8):1836-1846. doi: 10.1016/j.ejso.2021.03.229. Epub 2021 Mar 11. PubMed 33726951 ↗
  • Ursic K, Kos S, Kamensek U, Cemazar M, Miceska S, Markelc B, Bucek S, Staresinic B, Kloboves Prevodnik V, Heller R, Sersa G. Potentiation of electrochemotherapy effectiveness by immunostimulation with IL-12 gene electrotransfer in mice is dependent on tumor immune status. J Control Release. 2021 Apr 10;332:623-635. doi: 10.1016/j.jconrel.2021.03.009. Epub 2021 Mar 8. PubMed 33705828 ↗
  • Tremble LF, O'Brien MA, Soden DM, Forde PF. Electrochemotherapy with cisplatin increases survival and induces immunogenic responses in murine models of lung cancer and colorectal cancer. Cancer Lett. 2019 Feb 1;442:475-482. doi: 10.1016/j.canlet.2018.11.015. Epub 2018 Nov 22. PubMed 30472183 ↗
  • Justesen TF, Orhan A, Raskov H, Nolsoe C, Gogenur I. Electroporation and Immunotherapy-Unleashing the Abscopal Effect. Cancers (Basel). 2022 Jun 10;14(12):2876. doi: 10.3390/cancers14122876. PubMed 35740542 ↗
  • Falk H, Lambaa S, Johannesen HH, Wooler G, Venzo A, Gehl J. Electrochemotherapy and calcium electroporation inducing a systemic immune response with local and distant remission of tumors in a patient with malignant melanoma - a case report. Acta Oncol. 2017 Aug;56(8):1126-1131. doi: 10.1080/0284186X.2017.1290274. Epub 2017 Feb 22. No abstract available. PubMed 28562201 ↗
  • Tetzlaff MT, Messina JL, Stein JE, Xu X, Amaria RN, Blank CU, van de Wiel BA, Ferguson PM, Rawson RV, Ross MI, Spillane AJ, Gershenwald JE, Saw RPM, van Akkooi ACJ, van Houdt WJ, Mitchell TC, Menzies AM, Long GV, Wargo JA, Davies MA, Prieto VG, Taube JM, Scolyer RA. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018 Aug 1;29(8):1861-1868. doi: 10.1093/annonc/mdy226. PubMed 29945191 ↗
  • Di Gennaro P, Gerlini G, Urso C, Sestini S, Brandani P, Pimpinelli N, Borgognoni L. CD4+FOXP3+ T regulatory cells decrease and CD3+CD8+ T cells recruitment in TILs from melanoma metastases after electrochemotherapy. Clin Exp Metastasis. 2016 Dec;33(8):787-798. doi: 10.1007/s10585-016-9814-x. Epub 2016 Jul 30. PubMed 27475809 ↗
  • Bigi L, Galdo G, Cesinaro AM, Vaschieri C, Marconi A, Pincelli C, Fantini F. Electrochemotherapy induces apoptotic death in melanoma metastases: a histologic and immunohistochemical investigation. Clin Cosmet Investig Dermatol. 2016 Nov 23;9:451-459. doi: 10.2147/CCID.S115984. eCollection 2016. PubMed 27920565 ↗
  • Steele MM, Jaiswal A, Delclaux I, Dryg ID, Murugan D, Femel J, Son S, du Bois H, Hill C, Leachman SA, Chang YH, Coussens LM, Anandasabapathy N, Lund AW. T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control. Nat Immunol. 2023 Apr;24(4):664-675. doi: 10.1038/s41590-023-01443-y. Epub 2023 Feb 27. PubMed 36849745 ↗
  • Dimitrakopoulou-Strauss A. Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET-CT. Cancer Immunol Immunother. 2019 May;68(5):813-822. doi: 10.1007/s00262-018-2229-6. Epub 2018 Aug 19. PubMed 30123922 ↗
  • Weiss SA, Wolchok JD, Sznol M. Immunotherapy of Melanoma: Facts and Hopes. Clin Cancer Res. 2019 Sep 1;25(17):5191-5201. doi: 10.1158/1078-0432.CCR-18-1550. Epub 2019 Mar 28. PubMed 30923036 ↗
  • Campana LG, Peric B, Mascherini M, Spina R, Kunte C, Kis E, Rozsa P, Quaglino P, Jones RP, Clover AJP, Curatolo P, Giorgione R, Cemazar M, Terlizzi F, Bosnjak M, Sersa G. Combination of Pembrolizumab with Electrochemotherapy in Cutaneous Metastases from Melanoma: A Comparative Retrospective Study from the InspECT and Slovenian Cancer Registry. Cancers (Basel). 2021 Aug 25;13(17):4289. doi: 10.3390/cancers13174289. PubMed 34503099 ↗
  • Heppt MV, Eigentler TK, Kahler KC, Herbst RA, Goppner D, Gambichler T, Ulrich J, Dippel E, Loquai C, Schell B, Schilling B, Schad SG, Schultz ES, Matheis F, Tietze JK, Berking C. Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis. Cancer Immunol Immunother. 2016 Aug;65(8):951-9. doi: 10.1007/s00262-016-1856-z. Epub 2016 Jun 13. PubMed 27294607 ↗
  • Mozzillo N, Simeone E, Benedetto L, Curvietto M, Giannarelli D, Gentilcore G, Camerlingo R, Capone M, Madonna G, Festino L, Caraco C, Di Monta G, Marone U, Di Marzo M, Grimaldi AM, Mori S, Ciliberto G, Ascierto PA. Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy. Oncoimmunology. 2015 May 22;4(6):e1008842. doi: 10.1080/2162402X.2015.1008842. eCollection 2015 Jun. PubMed 26155423 ↗
  • Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, Saw RP, Thompson JF. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012 Jul 20;30(21):2678-83. doi: 10.1200/JCO.2011.37.8539. Epub 2012 Jun 18. PubMed 22711850 ↗
  • Park CK, Kim SK. Clinicopathological significance of intratumoral and peritumoral lymphocytes and lymphocyte score based on the histologic subtypes of cutaneous melanoma. Oncotarget. 2017 Feb 28;8(9):14759-14769. doi: 10.18632/oncotarget.14736. PubMed 28107203 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2023 (actual). Primary completion is estimated for Sep 2026, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2024
First posted
Apr 29, 2024
StartActual
Nov 10, 2023
Primary completionEst.
Sep 30, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06388252
Lead sponsor
Institute of Oncology Ljubljana
Collaborators
Slovenian Research Agency
Responsible party
Sponsor
First posted
Apr 29, 2024
Start date
Nov 10, 2023
Primary completion
Sep 30, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 19, 2026

Study contacts

Barbara Perić
principal investigator · Dep. of Surgical Oncology, Institute of Oncology Ljubljana

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion